Eye D drug delivery technology

Visc Has Entered Into an Option Agreement to License Aerie Controlled
Nov 7, 2012
ViSc, a subsidiary of BioLight Life Science Investments, has entered into an option agreement to license Aerie Pharmaceuticals' controlled-release Eye-D drug delivery technology. Under the license agreement, the technology, which will be ...

Tags: Eye-D drug delivery technology, Medicine